Medical/Pharmaceuticals
Recbio announces Phase III Clinical Trial Progress Of Recombinant HPV 9-Valent Vaccine
TAIZHOU, China, Aug. 10, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group", Stock code: 02179.HK) is pleased to announce that, the Company has recently completed the subject enrollment and first dose vaccination in respect of immun...
2022-08-10 16:06
2393
Starpharma signs new DEP® agreement with MSD
MELBOURNE, Australia, Aug. 10, 2022 /PRNewswire/ -- Australian biotechnology company Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC,Rahway, NJ, USA. This new DEP® program will generate and evaluate additional DEP® Antibod...
2022-08-10 15:29
1655
MedAlliance SELUTION SLR Receives Second FDA IDE Approval
GENEVA, Aug. 10, 2022 /PRNewswire/ -- SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval to initiate its pivotal clinical trial for the treatment of occlusive disease of the superficial femoral artery (SFA). ...
2022-08-10 10:00
2534
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Moderate-to-severe Plaque Psoriasis Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China, Aug. 10, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2022-08-10 08:00
2826
ONESIGHT ESSILORLUXOTTICA FOUNDATION ANNOUNCES PUBLICATION OF NEW ARTICLE
Article addresses role of advocacy in advancing healthy vision to meet Sustainable Development Goals DALLAS, Aug. 10, 2022 /PRNewswire/ -- OneSight EssilorLuxottica Foundation (Foundation) is pleased to announce the publication of a peer-reviewed article, The Power of Advocacy: Advancing Vision f...
2022-08-10 02:00
2159
Frost & Sullivan Institute Recognizes Samsung Biologics with the 2022 Global Enlightened Growth Leadership Award for its Commitment to Sustainable Growth
Samsung Biologics' mission to create a better world through high-quality biopharmaceuticals is underscored by a series of global initiatives to deliver progress related to climate change SAN ANTONIO, Aug. 9, 2022 /PRNewswire/ -- Frost & Sullivan Institute is proud to present Samsung Biologics wi...
2022-08-09 21:17
2372
Merck Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production Platform
* Reduces process development time by an estimated 40 percent * Enables biopharmaceutical companies to increase the speed to clinical manufacturing * Adds to company's best-in-class VirusExpress® Lentiviral Production Platform DARMSTADT,Germany, Aug. 9, 2022 /PRNewswire/ -- Merck, a leading s...
2022-08-09 20:00
2656
Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol®
HEIDELBERG, Germany, and CAMBRIDGE, MA, Aug. 9, 2022 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced the submission of a New Drug Application (NDA) to the U.S. Food and...
2022-08-09 19:00
1760
First Patient Dosed in Phase II Study of KN046 Combined with Axitinib for the First Line Treatment of Advanced Non-Small Cell Lung Cancer
SUZHOU, China, Aug. 9, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced the first patient has been dosed in the phase II clinical study (KN046-209) of PD-L1/CTLA-4 bispecific antibody KN046 plus Axitinib for the first line treatment of advanced Non-Small Cell Lung Cancer (NS...
2022-08-09 11:18
2965
Sciwind Biosciences Reports Positive Interim Results from Phase 1c/2a Clinical Trial of XW003 (Ecnoglutide) in Overweight and Obese Adult Volunteers in China
* Mean body weight loss of 9.6% and 9.0% in participants receiving 1.8 mg and 2.4 mg XW003 for 14 weeks, respectively * Up to 72.4% of participants achieved weight loss of at least 5% at week 14 * XW003 was safe and well tolerated with gastrointestinal side effects as the most commonly repor...
2022-08-09 08:00
2113
FRONTIER BIOTECHNOLOGIES ANNOUNCES POSITIVE PHASE 1 RESULTS OF ITS FIRST CORONAVIRUS MAIN PROTEASE (MPRO) SMALL MOLECULE INHIBITOR, LAYING FOUNDATION FOR THE TREATMENT OF ACUTE AND LONG COVID
* FB2001 (Bofutrelvir) is a Coronavirus Mpro inhibitor, which exhibited potent anti-SARS-CoV-2 activityin vitro and in vivo * Phase 1 results show FB2001 to be generally safe and well tolerated. No significant difference was observed between Chinese and American populations. Single-agent anti...
2022-08-09 00:00
2773
Prominent Stanford University scientist and cellular reprogramming innovator will oversee all research for Turn Bio
Vittorio Sebastiano, globally recognized for pioneering science, expands his role at company he co-founded as it moves closer to clinical research MOUNTAIN VIEW, Calif., Aug. 8, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreata...
2022-08-08 20:00
2166
Prenetics Launches Circle Snapshot, Simple At-home Blood Tests Using the World's First Push-Button and Painless Blood Collection Device
- Circle Snapshot, a patented, painless, at-home blood test with laboratory results delivered digitally. - The test utilises a CE-certified blood collection device, which is a proprietary micro-needle technology that draws capillary blood painlessly using a novel microfluidic extraction process....
2022-08-08 16:45
3149
Xinhua Silk Road: E. China's Wuxi city steps up biomedical industry development
BEIJING, Aug. 8, 2022 /PRNewswire/ -- The 2022 Taihu Bay Future Healthcare Conference held Thursday in Wuxi City in eastChina's Jiangsu Province witnessed the launch of Wuxi Intellectual Property Protection Center with 52 biomedical projects contracted, involving a total of more than30 billion yu...
2022-08-08 12:24
2368
Qmed Asia launches Qmed GO "Mini Clinics" to Solve Rising Employee Healthcare Costs
Disrupting the medical landscape through an innovative internet-enabled
clinical kiosk.
KUALA LUMPUR, Malaysia, Aug. 8, 2022 /PRNewswire/ -- Qmed Asia
2022-08-08 10:15
2490
BIO Asia-Taiwan 2022 concludes, marking another successful edition of the region's biggest bioindustry-focused conference and exhibition
Exhibition visitors surpass 100,000 people over 4 days BIO Asia–Taiwan success a testament to Taiwan's booming biotechnology industry TAIPEI, Aug. 8, 2022 /PRNewswire/ -- BIO Asia–Taiwan 2022, held at the TaiNEX 2 Exhibition Center, Nangang,Taipei, from 27-31 July, came to a successful conclusio...
2022-08-08 10:00
4901
BioDuro-Sundia and X-Chem enter partnership to launch DEL services in China for the discovery of new small molecule drugs
SHANGHAI, Aug. 8, 2022 /PRNewswire/ -- BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and X-Chem, a DEL technology pioneer in small molecule drug discovery, jointly announced the launch of DNA Encoded Compound Library (...
2022-08-08 09:06
2206
Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors
--ASC61 is an in-house developed oral PD-L1 small molecule inhibitor prodrug that showed significant antitumor efficacy in preclinical studies as a single agent in multiple animal models --ASC61-A treatment induced secretion of IFNγ in a concentration dependent manner with an EC50 of 2.86 nM. Ma...
2022-08-08 08:10
2137
CStone presents updated results of a registrational study of sugemalimab in patients with stage III NSCLC via oral presentation at WCLC 2022
* GEMSTONE-301 study result was presented at IASLC 2022 World Conference on Lung Cancer. In addition, the leading Principal Investigator ProfessorYi-Long Wu was invited to highlight key data in a press conference * In the final progression-free survival analysis, sugemalimab showed sustained ...
2022-08-08 08:08
2051
Transcenta Announces the Appointment of Dr. Caroline Germa as Executive Vice President, Global Medicine Development and Chief Medical Officer
SUZHOU, China, Aug. 8, 2022 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics,announces the appointment of Dr. ...
2022-08-08 08:00
2168
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 287 media titles]
2024-04-30 10:11
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
[Picked up by 274 media titles]
2024-04-24 17:09
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
[Picked up by 268 media titles]
2024-04-24 13:00
Most Read
Automation Anywhere Appoints Tim McDonough as Chief Marketing Officer to Drive Global Awareness and Growth for the Leader in AI-Powered Automation
2024-04-24 03:57
7873
INTAMSYS Becomes 3D Printing Equipment Supplier for the WORLDSKILLS LYON 2024 COMPETITION
2024-04-24 17:09
6964
Introducing Wacom Movink: The first OLED pen display, and the thinnest and lightest Wacom pen display ever
2024-04-24 13:00
4257
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2908